The Salvador-Warts-Hippo (SWH) pathway was first discovered in Drosophila melanogaster as a potent inhibitor of tissue growth. The SWH pathway is highly conserved between D. melanogaster and mammals, both in function and in the mechanism of signal transduction. The mammalian SWH pathway limits tissue growth by inhibiting the nuclear access and expression of the transcriptional co-activator, Yes-associated protein (YAP). Mutation and altered expression of SWH pathway proteins has been observed in several types of human cancer, but the contribution of these events to tumorigenesis has been unclear. Here we show that YAP can enhance the transformed phenotype of ovarian cancer cell lines and that YAP confers resistance to chemotherapeutic agents that are commonly used to treat ovarian cancer. We find that high nuclear YAP expression correlates with poor patient prognosis in a cohort of 268 invasive epithelial ovarian cancer samples. Segregation by histotype shows that the correlation between nuclear YAP and poor survival is predominantly associated with clear cell tumors, independent of stage. Collectively our findings suggest that YAP derepression contributes to the genesis of ovarian clear cell carcinoma and that the SWH pathway is an attractive therapeutic target.
Introduction
The Salvador-Warts-Hippo (SWH) pathway regulates tissue growth in both invertebrates and vertebrates (Tapon et al., 2002; Dong et al., 2007; Harvey and Tapon, 2007; Zhao et al., 2007; Oka et al., 2008) . The SWH pathway was discovered in Drosophila melanogaster genetic screens (Tapon et al., 2002) and has subsequently been shown to function similarly in mammals (Camargo et al., 2007; Dong et al., 2007; Zhao et al., 2007) . The first identified members of this pathway were the serine/threonine kinase, Warts (LATS1/LATS2 in mammals) and the scaffold protein, Salvador (SAV1) (Tapon et al., 2002) . These proteins, together with the Hippo (MST1/MST2) kinase (Harvey et al., 2003; Jia et al., 2003; Pantalacci et al., 2003; Udan et al., 2003; Wu et al., 2003) and the Wts-activator, Mob as tumor suppressor (MOBK1B) (Lai et al., 2005) , form the core kinase cassette of the SWH pathway. These proteins limit growth by repressing the activity of the Yorkie transcriptional co-activator protein (Huang et al., 2005) . Yorkie has two mammalian homologs, Yes-associated protein (YAP) and TAZ/WWTR1 (transcriptional co-activator with PDZ-binding motif/WW domain containing transcription regulator 1). LATS1 and LATS2 phosphorylate YAP on at least five sites, which represses YAP activity in two ways: (1) LATSphosphorylated YAP is retained in the cytoplasm in a 14-3-3 protein-dependent fashion (Dong et al., 2007; Zhao et al., 2007; Oka et al., 2008) ; (2) YAP protein levels are reduced as it is targeted for ubiquitin-mediated proteolysis when phosphorylated by LATS kinases . Upstream of the core D. melanogaster Hippo kinase cassette are multiple regulatory proteins including Fat, Dachsous, Kibra, Expanded and Merlin (Grusche et al., 2010) .
Several lines of evidence suggest that the SWH pathway is deregulated in, and contributes to, the formation of different cancers (Harvey and Tapon, 2007; Zeng and Hong, 2008) . Modulation of different tumor suppressor components of the SWH pathway can induce tumor formation in mice; deletion of SAV1 or MST1 and MST2 causes enlarged livers, followed by tumor formation (Zhou et al., 2009; Lee et al., 2010) , whereas mice mutant for LATS2 generate soft tissue sarcoma and ovarian stromal hyperplasia (St John et al., 1999) . In addition, tumor suppressor genes of the SWH pathway are mutated, or exhibit lower expression in different cancers and cancer cell lines. NF2 (merlin) is mutated in neurofibromatosis type II (Harvey and Tapon, 2007) ; SAV1 and MOBK1B are mutated in human and mouse cancer cell lines (Tapon et al., 2002; Lai et al., 2005) ; LATS1 and LATS2 expression is silenced in aggressive human breast cancers (Takahashi et al., 2005) ; reduced expression and deletion of human homologs of fat, FAT1 and FAT4 occurs in breast, oral and astrocytic cancers (Nakaya et al., 2007; Chosdol et al., 2009; Qi et al., 2009) .
Yorkie and YAP are potent inducers of tissue growth in developing D. melanogaster and mouse tissues, respectively, and YAP and TAZ display properties of classical oncogenes (Overholtzer et al., 2006; Zender et al., 2006; Chan et al., 2008; Lei et al., 2008) . YAP overexpression can induce anchorage-independent growth of non-transformed cell lines in soft agar, as well as growth-factor independent growth and epithelial to mesenchymal transition in MCF10A cells (Overholtzer et al., 2006) . YAP can also increase the ability of cultured epithelial cells to migrate (Overholtzer et al., 2006) . Overexpression of YAP in mouse liver and the gastrointestinal tract induces dramatic hyperplasia (Camargo et al., 2007; Dong et al., 2007) , and YAP is amplified in unbiased screens for cancer-promoting genes in mouse models of breast and liver cancer (Overholtzer et al., 2006; Zender et al., 2006) . The 11q22 region, where YAP resides, is amplified in different human cancers and cancer cell lines (Harvey and Tapon, 2007) . In addition, YAP protein is expressed at higher levels and is nuclear enriched in a large proportion of human cancers including ovarian, lung, colorectal, liver and prostate (Dong et al., 2007; Zhao et al., 2007; Steinhardt et al., 2008; Xu et al., 2009) . Elevated YAP expression has recently been shown to correlate with reduced survival in liver cancer and lung cancer (Xu et al., 2009; Wang et al., 2010) , but this type of analysis has not been extended to other cancer types.
Here we examine the contribution of deregulated SWH pathway activity to the genesis of human ovarian cancer. Ovarian cancer is the most lethal gynecological malignancy, and among women in Western countries, is the fifth most common cause of cancer death (Stewart and Kleihues, 2003) . Various histotypes of ovarian cancer have been defined; the most common is serous cystadenocarcinoma, and other major types are mucinous, clear cell and endometrioid. Using expression profiling, ovarian cancers have also been segregated into molecular subtypes that correlate with disease progression, and are thus, clinically relevant (Tothill et al., 2008) . Here we find that the SWH pathway oncogene, YAP, is expressed at high levels in its active nuclear localization in B14% of a cohort of 284 human ovarian cancer samples. Significantly, for the first time we report that high levels of nuclear YAP correlate with poor prognosis of ovarian cancer patients with clear cell tumors. Therefore nuclear YAP expression might serve as a prognostic indicator of the outcome of patients with ovarian clear cell cancer, and implies that derepression of YAP activity contributes to the genesis of this disease.
Results
YAP is necessary and sufficient for anchorageindependent growth of ovarian epithelial cancer cell lines Expression of the key growth-promoting protein of the SWH pathway, YAP, is expressed at elevated levels and is nuclear-enriched in human ovarian cancer, but the clinical relevance of YAP expression has not been addressed. Here we sought to determine the clinical relevance of altered activity of the SWH pathway in human ovarian cancer. Initially, we analyzed the biological properties of YAP in human ovarian cancer cell lines given that YAP has the capacity to transform other cell lines (Overholtzer et al., 2006) . We sought to determine the oncogenic potential of YAP in serous epithelial ovarian cancer cell lines by assessing anchorage-independent growth, sensitivity to chemotherapeutic agents, ability to overcome contact inhibition, cell migration and invasion. YAP activity was analyzed in eight serous epithelial ovarian cancer cell lines by assessing levels of YAP protein relative to phospho-S127-YAP. Both the level of YAP and ratio of YAP to phospho-S127-YAP varied greatly between cell lines (Figures 1a and b) . For further study, we chose cell lines with low baseline YAP activity (OVCA432, OVCAR5 and SKOV3) and the cell line that showed the highest baseline YAP activity (OVCAR8), based on the fact that it had less Hippo pathway-dependent inhibitory phosphorylation at S127.
To determine if YAP was sufficient to enhance the transformed phenotype of ovarian cancer cell lines we stably infected OVCA432, OVCAR5 and SKOV3 cells with an empty control vector, or with a vector expressing either wild-type YAP (the YAP2 L splice variant), WW domain mutant-YAP (YAP-WW1*2*), which can have lower or higher activity depending on the cell line (Zhang et al., 2009) , or activated YAP (YAP-S127A), which lacks a major LATS1/LATS2 phosphorylation site, and as a result accumulates in the nucleus where it can activate its cognate transcription factors (Dong et al., 2007; Zhao et al., 2007) ( Figure 1c and Supplementary Figure S1 ). When plated in low-melting agarose, OVCA432 cells infected with vector alone grew poorly. Overexpression of YAP increased growth in soft agar only marginally, whereas WW domain mutant YAP did not. Significantly, overexpression of YAP-S127A, which is resistant to SWH pathway mediated repression, increased the colony forming ability of OVCA432 cells by 35-fold and of OVCAR5 and SKOV3 cells by 2.4 fold and 1.6 fold, respectively ( Figure 1e and Supplementary Figure S1 ).
Given that OVCAR8 cells had relatively high YAP activity we reasoned that YAP might be a key driver of transformation in these cells. To investigate this we stably infected these cells with vectors expressing short hairpin (shRNA) directed against the YAP gene. In cells expressing YAP-shRNA-2, YAP protein levels were reduced by B35%, whereas in cells expressing YAP-shRNA-3, YAP protein was reduced by B62% compared with control cells expressing a scrambled shRNA construct (Figure 1d ). When plated in soft agar a statistically significant difference was not observed between OVCAR8-YAP-shRNA-2 cells and the parental cell line, whereas OVCAR8-YAPshRNA-3 cells formed 18% less colonies than the parental line ( Figure 1f ). This shows that OVCAR8 cells rely at least partially on YAP for their ability to grow in an anchorage-independent fashion.
YAP drives ovarian cancer X Zhang et al YAP allows serous ovarian cancer cells to overcome contact inhibition Cells with reduced SWH pathway activity fail to undergo contact inhibition, as do cells overexpressing YAP-S127A (Zhao et al., 2007) . To determine whether YAP overexpression allowed ovarian cancer cell lines to bypass contact inhibition, we plated OVCA432 cells expressing either a vector control, or YAP-S127A in RPMI-1640 plus 10% fetal bovine serum and counted them every 24 h. Both cell lines displayed similar proliferation rates until day 5, one day after they reached confluence. At this time the proliferation rate of control cells plateaued and cells began to die, whereas cells overexpressing YAP-S127A continued to proliferate, indicating that they had overcome contact inhibition and possessed a survival advantage (Figure 1g ). YAP levels were also necessary to promote proliferation in cells cultured at high density as OVCAR8 cell or cells expressing YAP-S127A (YAP) in g, or of control OVCAR 8 cells (con) or cells expressing YAP-sh3 in h, over 7 days. Each data point is the mean of two experiments. Error bars in e and f represent s.d., n ¼ 3, whereas statistically significant changes compared with control as determined by a t-test are denoted by *(Po0.05) or **(Po0.01).
YAP drives ovarian cancer X Zhang et al numbers where YAP had been depleted plateaued after day 5 whereas control OVCAR8 cells plateaued a day later ( Figure 1h ).
YAP confers resistance of serous ovarian cancer cell lines to cisplatin and Taxol
Primary treatment for ovarian cancer typically includes platinum-based drugs such as cisplatin or carboplatin, as well as the microtubule-stabilizing agent, Taxol. To determine whether altering YAP expression could affect sensitivity of ovarian cancer cell lines to cisplatin and Taxol, we grew cells in the presence of different concentrations of these drugs in normal media. Cell viability was measured by MTT assay, and apoptosis was examined by analyzing cleavage of the caspase substrate, poly ADP ribose polymerase (PARP). OVCA432 cells overexpressing YAP-S127A displayed greater survival when treated with either 6.6 mM or 13.2 mM cisplatin, or 5 nM Taxol, than control cells (Figures 2a and c) . Consistently, OVCA432 cells expressing YAP-S127A expressed marginally less cleaved PARP protein 24 or 48 h after treatment with either 6.6 mM cisplatin or 7.5 nM Taxol (Figures 2b and d ).
In addition we treated OVCAR8 cells expressing scrambled control or YAP-shRNA-2 or -3 with the same drugs. When YAP was partially knocked down with either YAP shRNA construct, the viability of OVCAR8 cells was lower than control cells when treated with 6.6 mM or 13.2 mM cisplatin ( Figure 2e ). A similar result was observed when these cells were treated with Taxol, except only the stronger knockdown construct, YAPshRNA3, caused reduced viability of OVCAR8 cells to Taxol at the lower dose of 2.5 nM (Figure 2g ). Consistently, OVCAR8 cells expressing YAP-shRNA-2 or -3 displayed elevated PARP cleavage 24 h post treatment with cisplatin or Taxol (Figures 2f and h) . In an independent assay we assessed the ability of each of these cell lines to form colonies when cultured in the presence of either Taxol or cisplatin. Consistent with our previous results, YAP conferred resistance to both cisplatin and Taxol when overexpressed in OVCA432 cells, or knocked down in OVCAR8 cells . Thus YAP depletion confers partial sensitivity of ovarian cancer cell lines to chemotherapeutic agents. This finding is consistent with what has been reported in MCF10A cells overexpressing YAP when treated with different apoptotic stimuli including cisplatin and Taxol (Overholtzer et al., 2006) . YAP drives ovarian cancer X Zhang et al YAP stimulates migration and invasion of serous ovarian cancer cell lines YAP can stimulate migration of MCF10A cells in both two-dimensional scratch assays and in transwell assays, and induce an invasive morphology of MCF10A colonies in three-dimensional Matrigel (Overholtzer et al., 2006; Zhang et al., 2009 ). These phenotypes indicated that YAP can induce an epithelial to mesenchymal transition (EMT). To determine whether YAP could stimulate similar phenotypes in serous ovarian cancer cell lines we subjected the same cell lines used in soft agar assays, to transwell assays. OVCA432 cells migrated 4.3 fold more when overexpressing YAP-S127A, than when expressing the vector control (Figure 3a) . OVCAR8 cells expressing YAP-shRNA-2 had no obvious difference in migration potential to control cells, whereas migration was compromised by 35% in OVCAR8 cells expressing YAP-shRNA-3 (Figure 3b ). Therefore YAP can enhance the migratory properties of ovarian cancer cell lines. To investigate this further, we analyzed expression of EMT markers in these cells and found subtle changes in the expression of the epithelial marker, b-catenin, but not E-cadherin or the mesenchymal marker, N-cadherin. b-catenin expression was reduced by 25% when YAP-S127A was overexpressed in OVCA432 cells and increased 1.2 fold in OVCAR8 cells that expressed YAP-shRNA-3 (Figure 3c ).
We also found that YAP could stimulate invasion of ovarian cancer cells when we assessed their ability to migrate in transwell assays in the presence of Matrigel. Overexpression of YAP-S127A increased the invasive ability of OVCA432 cells twofold (Figure 3d ). In accordance with a dependency of YAP in driving this invasive behavior in ovarian cancer cells, the invasive phenotype of OVCAR8 cells was reduced by 20% or 39% when expressing YAPshRNA-2 or YAPshRNA-3, respectively (Figure 3e ).
YAP protein expression in human ovarian cancer
Given that we observed that YAP was both necessary and sufficient to drive tumorigenesis of ovarian cancer cell lines, and had been reported to be expressed at elevated levels in primary human ovarian tumors (Dong et al., 2007; Steinhardt et al., 2008) , we sought to determine its clinical relevance. Initially we assessed the level and subcellular localization of YAP protein in 284 human ovarian cancer samples that were collected as part of a population-based Australian cohort (Tothill et al., 2008) . As described in the Materials and methods, YAP protein levels and subcellular localization varied across tumor samples (Figures 4a and b , and Supplementary Figure S2 and S3), and therefore tumor samples were classified into different groups according to their histopathological characteristics (Table 1 and  Supplementary Table S2 ). High levels of nuclear YAP were observed in 14% of the 284 ovarian tumor samples analyzed, whereas YAP was previously described to be expressed only at low levels in the cytoplasm of ovarian stromal and surface epithelial cells (Steinhardt et al., 2008) .
Restricting the access of YAP to the nucleus is a major mechanism by which the SWH pathway represses tissue growth (Dong et al., 2007; Lei et al., 2008) , and therefore the oncogenic potential of YAP is expected to be increased in tumors that harbor high levels of nuclear YAP. To investigate the mechanism by which YAP was elevated and more nuclear in ovarian cancer samples, we examined gene expression profiles from serous tumors that displayed either negative YAP staining (five tumors) or high nuclear YAP staining (19 tumors). One possible mechanism that we considered was that mRNA expression levels of SWH pathway genes are altered in ovarian cancers with high nuclear YAP; either by elevation of YAP or repression of SWH pathway tumor suppressor genes, some of which are silenced by promoter methylation in human cancers, for example, LATS1 and LATS2 (Takahashi et al., 2005) . However, no consistent changes in SWH pathway gene expression were identified between these two classes of tumors (Supplementary YAP drives ovarian cancer X Zhang et al Figure S4 ) suggesting that elevated nuclear YAP protein in the serous tumors analyzed here was caused by alternative mechanisms. Table S3 ). Transcriptional changes caused by YAP overexpression were determined previously in developing murine livers (Dong et al., 2007) , murine NIH-3T3 cells (Ota and Sasaki, 2008) and human MCF10A cells (Hao et al., 2008; Zhang et al., 2008) . To determine whether similar gene expression changes were observed in tumors that displayed high, versus negative, YAP tumors we examined a list of 50 genes whose expression was reported to change to a high degree in cells overexpressing YAP (Supplementary Table S4 ). Only two genes, BIRC2 and TNFAIP6, displayed similar changes in expression in serous tumors with high YAP as in published studies but after correcting for multiple testing, these gene expression changes were not statistically significant. Therefore validation of these expression changes requires examination of an independent set of ovarian tumors for which gene expression data and tumor samples suitable for immunohistochemistry are available. In addition, given that YAP transcriptional signatures vary widely across different cells and tissues (Ota and Sasaki, 2008) , these analyses would likely be improved by first identifying a YAP signature in ovarian cancer cells.
High levels of nuclear YAP protein correlate with poor prognosis in human ovarian cancer To determine the prognostic significance of YAP expression for patients with ovarian cancer, we assessed correlation between the YAP protein expression profile and clinically significant characteristics including survival, tumor stage, grade and residual disease status. Initially, Kaplan-Meier curves were used to plot progression free survival (PFS) for samples in three YAP groups (low, medium and high) and statistical significance was tested using Cox's proportional hazards model. Low and moderate groups showed similar survival characteristics (Supplementary Figure S5) and therefore these groups were merged. Thus the final classification scheme segregated tumor classes into two groups based on YAP immunochemistry: high and low. Significantly, we observed that high levels of nuclear YAP correlated with a reduced PFS in ovarian cancer patients (Supplementary Figure S6A) . YAP expression was consistently low in borderline or low malignant potential ovarian cancers. As low malignant potential cancers are associated with good prognosis, we removed these from our analysis to focus on invasive tumors. A Kaplan-Meier curve was used to plot PFS of invasive ovarian cancers only and significantly, high YAP expression still correlated with poor prognosis (Figure 4c ). We then examined the relationship of YAP staining, histotype, and PFS and observed the most significant association with outcome was with clear cell tumors (Figure 4d and Supplementary Figure S6) . Clear cell tumors also displayed a higher proportion of samples with high nuclear YAP expression than other histotypes (Supplementary Table S5 ). Further analysis showed that YAP staining was not associated with clear cell tumor stage or residual disease (Table 2) . Therefore in future studies that utilize a larger sample set of ovarian clear cell tumors it will be important to determine whether nuclear YAP staining is an independent prognostic marker for this disease.
YAP expression is not associated with grade or molecular subtype YAP is known to drive cell proliferation and organ growth (Camargo et al., 2007; Dong et al., 2007) , and therefore we sought to determine whether its nuclear expression correlated with grade of serous, endometrioid or clear cell tumors. Contingency tables were created and Fisher's exact tests were used to interrogate this hypothesis. We found no evidence of association between YAP staining and tumor grade in any of the histotypes (Supplementary Table S6 ). We previously established that serous ovarian tumors can be classified into more homogeneous and clinically relevant subtypes using gene expression profiling, but the molecular basis of these subtypes is not known (Tothill et al., 2008) . Given that YAP is a transcriptional co-activator protein that can activate different transcription factors we sought to determine whether YAP might contribute to the expression profile of different subtypes of serous tumors. A Fisher's exact test found no association with molecular subtype (Supplementary Table S7 ).
YAP influences migration and anchorage-independent growth of ovarian clear cell cancer cell lines Given that YAP correlated with lower PFS in ovarian clear cell cancer patients we sought to address whether YAP could also affect the tumorigenic potential of cell lines derived from these tumors. Therefore we conducted a series of experiments similar to those presented in Figures 1-3 and Supplementary Figure S1 on serous cell lines. YAP activity varied across six ovarian clear cell cancer cell lines as determined by the ratio of YAP to phospho-YAP (Figures 5a and b) . As before, we generated stable cell lines that overexpressed YAP-S127A in cells predicted to have lower YAP activity (ES-2 and TOV-21G cells) as well as JSOC9 cells (which were predicted to have higher YAP activity) with scrambled control or YAP shRNA constructs (Figures  5c and d) . We analyzed expression of EMT markers in these cells and found subtle changes consistent with a reduced epithelial phenotype in YAP-overexpressing cells, and an enhanced epithelial phenotype in cells where YAP was depleted; E-cadherin and b-catenin were reduced by 42 and 50%, respectively, in TOV-21G cells that overexpressed YAP-S127A, whereas these proteins were elevated by twofold and 1.1 fold, respectively, in JSOC9 cells where YAP was knocked down by shRNA compared with control cells. Ncadherin expression was not detected in TOV-21G cells and was unaltered in JSOC9 cells. Consistent with these results we found that TOV-21G cells displayed enhanced migration capacity in transwell assays when they overexpressed YAP-S127A, whereas the migration capacity of JSOC9 cells was repressed when YAP expression was knocked down (Figures 5e and f) .
When the clear cell lines described above were plated in soft agar we observed a similar dependency on YAP for anchorage-independent growth. YAP-S127A overexpression in TOV-21G and ES-2 cells stimulated an increased ability to grow in soft agar (Figure 5g and Supplementary Figure S7) , whereas JSOC9 cells Quantitation of TOV-21G (g) and JSOC9 (h) colonies expressing the indicated plasmids grown in soft agar. Error bars in e-h represent s.d., n ¼ 3, whereas statistically significant changes compared with control as determined by a t-test are denoted by * (Po0.05) or ** (Po0.01).
YAP drives ovarian cancer X Zhang et al expressing YAP-shRNA-2 (but not YAP-shRNA-3) displayed a reduced capacity to form colonies in soft agar (Figure 5h ).
YAP confers resistance of clear cell ovarian cancer cell lines to cisplatin and Taxol
To determine whether the sensitivity of ovarian clear cell cancer lines to cisplatin and Taxol was responsive to YAP levels we cultured these cells with differing doses of these drugs. In untreated cells there were no differences in viability of each cell line as determined by MTT assay (Figures 6a, c, e and g) . A statistically significant increase in viability was detected in TOV-21G cells that overexpressed YAP-S127A when treated with 4.5 mM cisplatin, but not at other doses of cisplatin (Figure 6a ) or different doses of Taxol (Figure 6c ). Subtle changes in apoptotic markers were observed in these cells when treated with either 6.6 mM of cisplatin or 7.5 nM of Taxol; cleaved PARP and caspase 3 was slightly lower in YAP-S127A-expressing TOV-21G cells treated with cisplatin (Figure 6b ), whereas cleaved PARP was lower in YAP-S127A-expressing cells treated with Taxol (Figure 6d ). More obvious effects on apoptosis were observed in JSOC9 cells where YAP expression was depleted. Compared with control cells, YAP-depleted JSOC9 cells exhibited reduced viability when treated with 4.5 mM cisplatin (Figure 6e ), or with 10 nM, 60 nM or 80 nM Taxol (Figure 6g ). Concordantly, we observed subtle increases in cleaved caspase 3 and PARP in JSOC9 YAP-depleted cells treated with 4.5 mM cisplatin (Figure 5f ) or 30 nM Taxol (Figure 5h ) compared with control cells treated with the same doses of these drugs.
Discussion
The SWH pathway is a key regulator of tissue growth and has been implicated in human tumorigenesis. The upstream pathway component, Merlin, is mutated in neurofibromatosis type 2, whereas other SWH pathway genes have been reported to be mutated in human cancer cell lines or epigenetically silenced in human tumors (Harvey and Tapon, 2007) . SWH pathway deregulation can induce tumor formation in mice, but currently we lack a full appreciation of the significance of this pathway for human tumorigenesis. Previous studies reported high, and more nuclear, YAP protein expression in different human tumors including lung, ovarian, colon, liver, pancreas and prostate (Dong et al., 2007; Zhao et al., 2007; Steinhardt et al., 2008; Xu et al., 2009) , implying that SWH pathway activity is deregulated in these tumors and contributes to their formation. To date, however, only two studies have formally tested an association with YAP expression and patient prognosis. In these studies, nuclear YAP was shown to correlate with poor prognosis of patients with hepatocellular carcinoma or non-small-cell lung cancer (Xu et al., 2009; Wang et al., 2010) , but until now this type of analysis has not been performed in other cancers.
Here we interrogated the role of the SWH pathway in human ovarian cancer. Gain and loss-of-function experiments showed that YAP could modulate contact inhibition, enhance colony formation and migration, and increase resistance to chemotherapeutic agents in ovarian cancer cell lines (Figures 1, 2, 3, 5 and 6 ). The SWH pathway inhibits YAP transcriptional coactivator function by causing it to be sequestered in the cytoplasm (Dong et al., 2007; Zhao et al., 2007) , and therefore nuclear YAP expression provides a read-out of SWH pathway activity. We found YAP to be expressed at high levels in the nucleus of B14% of 284 human ovarian cancer samples analyzed and that elevated levels of nuclear YAP correlated with poor prognosis of ovarian cancer patients (Figure 4 ). Interestingly this correlation could largely be explained by a group of 25 clear cell tumors, suggesting that elevated YAP activity might contribute to the genesis of this disease. Ovarian clear cell cancer is associated with resistance to chemotherapy and poor prognosis (Tan and Kaye, 2007) . We found that nuclear YAP was independent of the stage of clear cell cancer, thus ruling out the possibility that nuclear YAP was simply a marker of advanced clear cell disease. Our study provides preliminary evidence that nuclear YAP might serve as an independent prognostic marker for ovarian clear cell cancer. The significance of YAP to ovarian clear cell cancer biology and its utility as a bio marker awaits verification in a larger cohort of these tumors. Interestingly the SWH pathway genes SAV1 and NF2 were previously shown to be mutated in clear cell renal cell carcinoma (Tapon et al., 2002; Dalgliesh et al., 2010) . Given that transcriptional profiling studies have found that the signature of ovarian clear cell tumors is more similar to renal clear cell tumors than other ovarian cancer histotypes (Zorn et al., 2005) , our studies, coupled with the findings of Tapon et al., and Dalgliesh et al., suggest that deregulation of Hippo pathway activity could be a key driver of clear cell cancer formation in different organs.
Although we did not observe an association of YAP expression with clinical outcome in serous cancers, it is obvious that there are very distinct differences in the level and subcellular localization of YAP in ostensibly equivalent high grade serous cancers. The notion that nuclear YAP has an important role in the biology of serous cancers is supported by our gain and loss of function cell line experiments (Figures 1-3) . If enriched nuclear YAP does contribute to tumorigenesis of a class of serous cancers then this implies that in high-grade serous tumors with little detectable YAP staining other oncogenic drivers must supplant activated YAP.
The observation that YAP protein expression and subcellular localization varies across ovarian tumors raises interesting questions about the molecular drivers of these events. LATS1/2 mediated phosphorylation of YAP has a dual effect: it limits YAP expression by targeting it for ubiquitin-mediated degradation , and creates a 14-3-3 binding site on YAP, thus limiting nuclear entry (Dong et al., 2007; Zhao et al., 2007) . In tumors that accumulate high cytoplas-YAP drives ovarian cancer X Zhang et al mic YAP we predict that either YAP mRNA levels are increased or that proteins involved in YAP degradation are impaired. YAP transcription was recently shown to be elevated in human medulloblastomas with increased Sonic Hedgehog pathway activity, defining a precedent for transcriptional activation of YAP in cancerous cells (Fernandez et al., 2009) . Those tumors that possess elevated nuclear YAP are more likely to be defective in central components of the SWH pathway, either due to reduced gene expression or as a result of mutational inactivation. The former possibility seems unlikely in ovarian cancer given that we observed no correlation between known SWH pathway tumor suppressor genes and tumors with high levels of nuclear YAP. Somatic mutation of SWH pathway genes remains a possibility and interestingly, mutations have been reported in the kinase domains of the core SWH pathway kinases, LATS2 and MST2, in human ovarian tumors: of 26 human ovarian cancer samples sequenced, a heterozygous nonsense mutation of LATS2 was found in a mucinous carcinoma and a heterozygous missense mutation in STK3 (MST2) was discovered in a clear cell carcinoma (Greenman et al., 2007) . Sequencing SWH pathway genes in larger cohorts of ovarian tumors should shed light on whether elevated nuclear YAP expression in tumors is caused by SWH pathway repression or another mechanism. Given that the SWH tumor suppressor pathway was only discovered 8 years ago in flies (Tapon et al., 2002) , tremendous progress has been made on understanding its biological function in different organisms and in normal and diseased tissues. Our study highlights the potential for YAP as a therapeutic target in ovarian cancer, particularly as reducing YAP levels can partially revert tumorigenic properties of ovarian cancer cell lines such as anchorageindependent growth, resistance to chemotherapeutic drugs, and cell migration and invasion. The TEAD1-4 transcription factors are major effectors of YAP, and the structure of YAP in complex with different TEAD family members was recently reported Li et al., 2010; Tian et al., 2010) . Small molecules that inhibit the YAP/ TEAD interaction might thus prove beneficial for treatment of cancers with enhanced YAP activity, such as ovarian clear cell cancer.
Materials and methods
Expression plasmids YAP plasmids were described previously (Zhang et al., 2009) . YAP shRNA plasmids were designed following an Open Biosystems protocol and cloned into the low malignant potential retroviral vector.
The shRNA sequences were: YAP-shRNA-1: (Zhang et al., 2009) . Stably infected pools of each cell line were used for subsequent experiments. Apoptosis was induced by treating cells with cisplatin (Institute of Drug Technology, Melbourne, Australia), or Taxol (Bristol Myers Squibb, Noble Park North, VIC, Australia). Cell viability was measured by MTT assay (Sigma Aldrich, St Louis, MO, USA) 48 h after treatment and colony forming assay was performed as described previously . Transwell cell migration assays were performed as previously described (Chan et al., 2008) . Both transwell and invasion assays used suspensions of 1 Â 10 5 cells in medium with 0.5% fetal bovine serum and complete medium with 20% fetal bovine serum as a chemoattactant. Invasion assays used chambers that were pre-coated with a thin layer of Matrigel Basement Membrane Matrix (BD Biosciences, Bedford, MA, USA) diluted in serum free medium. Cells remaining on the lower surface of membranes were trypsinized and counted after 24 h.
Immunoblotting
Whole cell lysates were subjected to SDS polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride and probed with antibodies that detected YAP, phospho-S127-YAP, PARP and cleaved caspase 3 (Cell Signaling, Danvers, MA, USA), E-cadherin and b-catenin (BD Transduction Laboratories, Bedford, MA, USA), actin (MP Biomedicals, Seven Hills, NSW, Australia) and N-cadherin (Upstate Biotechnology, Lake Placid, NY, USA).
Tissue microarray and histopathology
Tissue microarrays were constructed as previously described (Tothill et al., 2008) . Patients with epithelial ovarian, primary peritoneal or fallopian tube cancer, diagnosed between 1992 and 2006, were identified through the Australian Ovarian Cancer Study (AOCS). Individual cases were subject to central pathology review by either light microscopy assessment of representative formalin fixed tissue material. A summary of clinical details is provided in Supplementary Table S1 . Institutional Review Board approval was obtained for patient consent and sample collections at respective institutions. YAP protein expression was assessed on 284 ovarian tumor samples (Supplementary Materials and methods), which were scored depending on the level of cytoplasmic and nuclear staining: negative-no or weak staining; moderate-definite cytoplasmic staining with o50% nuclear staining; high->50% nuclear and definite cytoplasmic staining. Representative staining patterns are shown in Supplementary Figure S1 . The distribution of samples into these various classes is shown in Table 1 and Supplementary Table S2 .
Statistical analysis
Kaplan-Meier curves were used to plot the survival curves for samples in each group using the functions available in R package survival (Ihaka and Gentleman, 1996) . Cox proportional hazards regression model was used to compute the statistical significance of the difference in survival characteristics. Fisher's exact test was used to test the association between YAP staining and factors such as grade, stage and residual disease.
Microarray analysis
Gene expression patterns of 24 ovarian tumor samples present on TMAs were previously assayed using Affymetrix U133plus_2 arrays (Affymetrix, Santa Clara, CA, USA) (Tothill et al., 2008) . Genes that were differentially expressed between samples with high nuclear YAP and samples with no YAP expression were identified using an empiric Bayes-moderated t-statistic available in the Limma package (Smyth, 2004 (Smyth, , 2005 . The false discovery rate was controlled using the Benjamini and Hochberg algorithm (Reiner et al., 2003) . The top 1000 genes from this analysis are presented in Supplementary Table S3. 
